MX2013010444A - Superar la resistencia a inhibidores de la via erbb. - Google Patents

Superar la resistencia a inhibidores de la via erbb.

Info

Publication number
MX2013010444A
MX2013010444A MX2013010444A MX2013010444A MX2013010444A MX 2013010444 A MX2013010444 A MX 2013010444A MX 2013010444 A MX2013010444 A MX 2013010444A MX 2013010444 A MX2013010444 A MX 2013010444A MX 2013010444 A MX2013010444 A MX 2013010444A
Authority
MX
Mexico
Prior art keywords
inhibitor
erbb
resistance
egfr
erbb pathway
Prior art date
Application number
MX2013010444A
Other languages
English (en)
Spanish (es)
Inventor
Bo Zhang
Gabriela Garcia
William Kubasek
Victor Moyo
Gavin Macbeath
Maria Johanna Lahdenranta
Charlottee Mcdonagh
Matthew David Onsum
Mark Sevecka
Marisa Wainszelbaum
Birgit Schoeberl
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2013010444A publication Critical patent/MX2013010444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013010444A 2011-03-15 2012-03-15 Superar la resistencia a inhibidores de la via erbb. MX2013010444A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452976P 2011-03-15 2011-03-15
US201161452974P 2011-03-15 2011-03-15
PCT/US2012/029292 WO2012125864A2 (en) 2011-03-15 2012-03-15 Overcoming resistance to erbb pathway inhibitors

Publications (1)

Publication Number Publication Date
MX2013010444A true MX2013010444A (es) 2014-03-21

Family

ID=45953230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010444A MX2013010444A (es) 2011-03-15 2012-03-15 Superar la resistencia a inhibidores de la via erbb.

Country Status (13)

Country Link
US (1) US20150231238A1 (enExample)
EP (2) EP2686015A2 (enExample)
JP (1) JP2014509593A (enExample)
KR (1) KR20140023921A (enExample)
CN (1) CN103429262A (enExample)
AU (1) AU2012229062A1 (enExample)
BR (1) BR112013022887A2 (enExample)
CA (1) CA2828043A1 (enExample)
EA (1) EA201301025A1 (enExample)
IL (1) IL228393A0 (enExample)
MX (1) MX2013010444A (enExample)
SG (1) SG192775A1 (enExample)
WO (1) WO2012125864A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678181C (en) 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
AU2011224186C1 (en) 2010-03-11 2015-04-02 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP3974832A1 (en) 2011-10-06 2022-03-30 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
EP2804624B1 (en) * 2012-01-19 2018-12-26 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US11305012B2 (en) * 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
JP2016540993A (ja) * 2013-09-30 2016-12-28 第一三共株式会社 タンパク質生体マーカー及びその使用
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
IL301147A (en) * 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
BR112016025056A2 (pt) * 2014-05-14 2018-02-20 F. Hoffmann-La Roche Ag uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3166630A4 (en) 2014-07-07 2018-03-28 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
JP2018513155A (ja) * 2015-04-17 2018-05-24 メリマック ファーマシューティカルズ インコーポレーティッド セリバンツマブを用いた併用療法
CN108290930A (zh) * 2015-05-01 2018-07-17 胡文聪 Pink1 c末端结构域多肽及其用于癌症治疗的方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017035482A1 (en) * 2015-08-27 2017-03-02 Merrimack Pharmaceuticals, Inc Combination therapies for treatment of heregulin positive cancers
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
AU2018271157C1 (en) 2017-05-17 2021-11-18 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
TWI874301B (zh) 2017-08-09 2025-03-01 荷蘭商美勒斯公司 結合表皮生長因子受體(EGFR)及cMET的抗體
WO2019088348A1 (ko) * 2017-11-06 2019-05-09 한국과학기술원 Egfr 저해제 저항성 암 치료제
US20220372166A1 (en) * 2019-10-24 2022-11-24 Merus N.V. Means and methods for treating subjects with her2 and her3 positive cancer
AR127893A1 (es) * 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2480099C (en) 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2678181C (en) 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
ES2582386T3 (es) 2007-03-01 2016-09-12 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
EP2155877A2 (en) 2007-05-11 2010-02-24 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
RU2568051C2 (ru) 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. АНТИТЕЛА К ErbB3
MX347981B (es) * 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
US20140056898A1 (en) * 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents

Also Published As

Publication number Publication date
US20150231238A1 (en) 2015-08-20
IL228393A0 (en) 2013-12-31
EP2815765A1 (en) 2014-12-24
WO2012125864A2 (en) 2012-09-20
SG192775A1 (en) 2013-09-30
AU2012229062A1 (en) 2013-04-11
CN103429262A (zh) 2013-12-04
KR20140023921A (ko) 2014-02-27
JP2014509593A (ja) 2014-04-21
CA2828043A1 (en) 2012-09-20
EP2686015A2 (en) 2014-01-22
WO2012125864A3 (en) 2012-12-27
BR112013022887A2 (pt) 2016-12-06
EA201301025A1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2013010444A (es) Superar la resistencia a inhibidores de la via erbb.
CA2871471C (en) Dna-pk inhibitors
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
UA115176C2 (uk) Інгібітори протеїнкінази
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX357502B (es) Derivados de pirrolotriazinona.
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2014007829A (es) Compuestos triciclicos fusionados como inhibidores de cinasa raf.
MX362939B (es) Derivados de (aza-)isoquinolinona.
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
MX377618B (es) Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX344302B (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний